Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stamatios Theocharis

Showing results (1-10 of 282) with videos related to

Pageof 29
Sort By:
Expert Opinion on Therapeutic Targets|December 23, 2018
The farnesoid X receptor: a potential target for expanding the therapeutic arsenal against kidney diseaseChristos Masaoutis, Stamatios Theocharis
Disease Markers|September 6, 2019
The Role of Exosomes in Bone Remodeling: Implications for Bone Physiology and DiseaseChristos Masaoutis, Stamatios Theocharis
Nutrition and Cancer|November 3, 2011
Current evidence on the anticancer potential of Chios mastic gumConstantinos Giaginis, Stamatios Theocharis
Expert Opinion on Therapeutic Targets|July 18, 2009
Primary liver tumors: origin and target therapyMichail Papoulas, Stamatios Theocharis
Expert Opinion on Investigational Drugs|March 2, 2021
Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatmentChristos Masaoutis, Stefania Kokkali, Stamatios Theocharis
World Journal of Gastroenterology|August 29, 2006
Insights on augmenter of liver regeneration cloning and functionElisavet Gatzidou, Gregory Kouraklis, Stamatios Theocharis
Expert Opinion on Investigational Drugs|October 10, 2007
Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesisCostas Giaginis, Alexandra Margeli, Stamatios Theocharis
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|June 29, 2010
Ghrelin, another factor affecting bone metabolismDimitrios Nikolopoulos, Stamatios Theocharis, Gregory Kouraklis
Current Molecular Medicine|September 11, 2008
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injuryCostas Giaginis, Gerasimos Tsourouflis, Stamatios Theocharis
Histology and Histopathology|June 1, 2012
Farnesoid X Receptor (FXR) from normal to malignant stateIoannis Koutsounas, Constantinos Giaginis, Stamatios Theocharis
Pageof 29

Showing results (1-10 of 282) with videos related to

Sort By:
Pageof 29
Expert Opinion on Therapeutic Targets|December 23, 2018
The farnesoid X receptor: a potential target for expanding the therapeutic arsenal against kidney diseaseChristos Masaoutis, Stamatios Theocharis
Disease Markers|September 6, 2019
The Role of Exosomes in Bone Remodeling: Implications for Bone Physiology and DiseaseChristos Masaoutis, Stamatios Theocharis
Nutrition and Cancer|November 3, 2011
Current evidence on the anticancer potential of Chios mastic gumConstantinos Giaginis, Stamatios Theocharis
Expert Opinion on Therapeutic Targets|July 18, 2009
Primary liver tumors: origin and target therapyMichail Papoulas, Stamatios Theocharis
Expert Opinion on Investigational Drugs|March 2, 2021
Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatmentChristos Masaoutis, Stefania Kokkali, Stamatios Theocharis
World Journal of Gastroenterology|August 29, 2006
Insights on augmenter of liver regeneration cloning and functionElisavet Gatzidou, Gregory Kouraklis, Stamatios Theocharis
Expert Opinion on Investigational Drugs|October 10, 2007
Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesisCostas Giaginis, Alexandra Margeli, Stamatios Theocharis
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|June 29, 2010
Ghrelin, another factor affecting bone metabolismDimitrios Nikolopoulos, Stamatios Theocharis, Gregory Kouraklis
Current Molecular Medicine|September 11, 2008
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injuryCostas Giaginis, Gerasimos Tsourouflis, Stamatios Theocharis
Histology and Histopathology|June 1, 2012
Farnesoid X Receptor (FXR) from normal to malignant stateIoannis Koutsounas, Constantinos Giaginis, Stamatios Theocharis
Pageof 29